High-throughput screening platform for anticancer therapeutic drug cytotoxicity

Assay and Drug Development Technologies

Volumn 6, Issue 5, 2008, Pages 711-721

  Sekhon, Bhagwant Kaur ^a   Roubin, Rebecca Heidi ^a   Tan, Aaron ^a   Chan, Wing Keung ^b   Sze, Daniel Man Yuen ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL;

EID: 57049161490     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2008.148     Document Type: Article

References (19)

1. McAvoy B, Elwood M, Staples M: Cancer in Australia - an update for GPs. Aust Fam Physician 2005;34:41-45.
2. Butler MS: Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep 2005;22:162-195.
3. Gullo VP, McAlpine J, Lam KS, Baker D, Petersen F: Drug discovery from natural products. J Ind Microbiol Biotechnol 2006;33:523-531.
4. Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-477.
5. Tan A, Sze DM: Indigenous herbs and cancer. J Complement Med 2008;7:48-50.
6. Miller K, Neilan B, Sze DM: Development of taxol and other endophyte produced anti-cancer agents. Recent Patents Anticancer Drug Discov 2008;3:14-19.
7. Sze DMY, Brown R, Yang S, Ho PJ, Gibson J, Joshua D: The use of thalidomide in myeloma therapy as an effective anticancer drug. Curr Cancer Drug Targets 2006;6:325-331.
8. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-4530.
9. Sze DM, Brown RD, Yuen E, Gibson J, Ho J, Raitakari M, et al.: Clonal cytotoxic T cells in myeloma. Leuk Lymphoma 2003;44:1667-1674.
10. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
11. Cory AH, Owen TC, Barltrop JA, Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-212.
12. Lundin A, Hasenson M, Persson J, Pousette A: Estimation of biomass in growing cell lines by adenosine triphosphate assay. Methods Enzymol 1986;133:27-42.
13. Augustine NH, Pasi BM, Hill HR: Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin. J Clin Lab Anal 2007;21:265-270.
14. Petty RD, Sutherland LA, Hunter EM, Cree IA: Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin 1995;10:29-34.
15. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Wood RA, et al.: Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993;19:242-249.
16. Kuzmits R, Aiginger P, Muller MM, Steurer G, Linkesch W: Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells. Clin Sci (Lond) 1986;71:81-88.
17. Green LM, Reade JL, Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 1984;70:257-268.
18. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM: A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 1994;174:311-320.
19. Skipper HE, Schabel FMJ, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, et al.: Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54:431-450.